Literature DB >> 26407681

Southern copperhead venom enhances tissue-type plasminogen activator induced fibrinolysis but does not directly lyse human plasma thrombi.

Vance G Nielsen1.   

Abstract

In addition to degrading fibrinogen as a source of consumptive coagulopathy, purified fractions of southern copperhead (Agkistrodon contortrix contortrix; A. c. contortrix) venom has been demonstrated to enhance fibrinolysis. The goal of this investigation was to characterize the kinetic fibrinolytic profile of A. c. contortrix venom in the absence and presence of tissue-type plasminogen activator (tPA) to determine if intact venom had tPA independent fibrinolytic properties. Utilizing thrombelastographic methods, the coagulation and fibrinolytic kinetic profiles of human plasma exposed to A. c. contortrix venom (0-6 μg/ml) were determined in the absence or presence of tPA (0-100 IU/ml). Then, plasma was exposed to 0-6 μg/ml of venom without tPA added and coagulation observed for 3 h. Venom significantly prolonged the onset of coagulation, decreased the velocity of thrombus growth but did not significantly decrease clot strength. In the presence of tPA, venom significantly decreased clot strength, shortened the time of onset of fibrinolysis, decreased clot lysis time but did not significantly affect the maximum rate of lysis. Lastly, while venom exposure in the absence of tPA significantly prolonged the onset of coagulation and decreased the velocity of clot growth, venom exposure did not result in detectable fibrinolysis over the 3 h observation period. A. c. contortrix venom enhances tPA mediated fibrinolysis by degrading plasma coagulation kinetics. Intact A. c. contortrix venom does not possess sufficient fibrinolytic activity to cause fibrinolysis in human plasma at the concentration tested.

Entities:  

Keywords:  Fibrinogenolysis; Fibrinolysis; Snake venom; Thrombelastography; Tissue-type plasminogen activator

Mesh:

Substances:

Year:  2016        PMID: 26407681     DOI: 10.1007/s11239-015-1287-2

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  12 in total

1.  Snake bites and hemostasis/thrombosis.

Authors:  Ryan J R McCleary; R Manjunatha Kini
Journal:  Thromb Res       Date:  2013-09-27       Impact factor: 3.944

Review 2.  Snake venom metalloproteinases.

Authors:  Francis S Markland; Stephen Swenson
Journal:  Toxicon       Date:  2012-09-18       Impact factor: 3.033

3.  Screening for fibrinolytic activity in eight Viperid venoms.

Authors:  M S Ramírez; E E Sánchez; C García-Prieto; J C Pérez; G R Chapa; M R McKeller; R Ramírez; Y De Anda
Journal:  Comp Biochem Physiol C Pharmacol Toxicol Endocrinol       Date:  1999-09

4.  Venom from southern copperhead snake (Agkistrodon contortrix contortrix). I. Characterization of a protease that preferentially releases fibrinopeptide B.

Authors:  A Shimizu; E C Jimenez; J Takagi; Y Inada; Y Saito
Journal:  Toxicon       Date:  1987       Impact factor: 3.033

5.  Elastic modulus-based thrombelastographic quantification of plasma clot fibrinolysis with progressive plasminogen activation.

Authors:  Vance G Nielsen; Benjamin M Cohen; Eli Cohen
Journal:  Blood Coagul Fibrinolysis       Date:  2006-01       Impact factor: 1.276

6.  Intravenous ancrod for acute ischaemic stroke in the European Stroke Treatment with Ancrod Trial: a randomised controlled trial.

Authors:  Michael G Hennerici; Richard Kay; Julien Bogousslavsky; Gian Luigi Lenzi; Marc Verstraete; Jean Marc Orgogozo
Journal:  Lancet       Date:  2006-11-25       Impact factor: 79.321

7.  Thrombin-like and fibrinolytic enzymes in the venoms from the Gaboon viper (Bitis gabonica), eastern cottonmouth moccasin (Agkistrodon p. piscivorus) and southern copperhead (Agkistrodon c. contortrix) snakes.

Authors:  S S Bajwa; H Kirakossian; K N Reddy; F S Markland
Journal:  Toxicon       Date:  1982       Impact factor: 3.033

8.  Boomslang bite--diagnosis and management. A report of 2 cases.

Authors:  J M Aitchison
Journal:  S Afr Med J       Date:  1990-07-07

9.  Ancrod in acute ischemic stroke: results of 500 subjects beginning treatment within 6 hours of stroke onset in the ancrod stroke program.

Authors:  David E Levy; Gregory J del Zoppo; Bart M Demaerschalk; Andrew M Demchuk; Hans-Christoph Diener; George Howard; Markku Kaste; Arthur M Pancioli; E Bernd Ringelstein; Carmen Spatareanu; Warren W Wasiewski
Journal:  Stroke       Date:  2009-10-29       Impact factor: 7.914

Review 10.  Fibrolase: trials and tribulations.

Authors:  Francis S Markland; Steve Swenson
Journal:  Toxins (Basel)       Date:  2010-04-20       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.